Please login to the form below

Not currently logged in
Email:
Password:

Acorda

This page shows the latest Acorda news and features for those working in and with pharma, biotech and healthcare.

Biotech leaders jump into US free speech debate

Biotech leaders jump into US free speech debate

Alnylam chief executive John Maraganore, Decibel Therapeutics’CEO Steve Holtzman, Acorda CEO Ron Cohen and Jeremy Levin of Ovid Therapeutics are the main signatories to the letter published In Nature, but

Latest news

  • Biogen pays $590m for Pfizer cognition drug Biogen pays $590m for Pfizer cognition drug

    The biotech company has also been linked to a possible takeover offer for Acorda Therapeutics and its Parkinson’s diseases candidates Inbrija (inhaled levodopa) and SYN-201.

  • Acorda acquires Biotie to expand in Parkinson's disease Acorda acquires Biotie to expand in Parkinson's disease

    Acorda acquires Biotie to expand in Parkinson's disease. Strikes $363m deal for Finnish firm. ... Acorda Therapeutics has agreed to buy Finland's Biotie Therapies in a $363m deal that swells its pipeline of Parkinson's disease (PD) drug candidates.

  • Pharma deals for February 2012 Pharma deals for February 2012

    For example, the acquisition of the privately-owned Neuronex, with its diazepam nasal spray, by Acorda Therapeutics reads like a licensing deal: $2m upfront; some R&D payments; $18m development and ... 300. Neuronex / Acorda. Collaboration and license.

  • Multiplying options for MS

    Acorda and Biogen Idec's Ampyra (fampridine sustained-release), a potassium channel antagonist that has been shown to restore conduction in demyelinated axons in patients with MS, was approved in the

  • A competitive edge

    Ampyra (Acorda Therapeutics). Multiple sclerosis. USA, Puerto Rico. Desirudin . Iprivask (Canyon Pharmaceuticals).

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Dr Catherine Strader joins Acorda Therapeutics’ board Dr Catherine Strader joins Acorda Therapeutics’ board

    Dr Catherine Strader joins Acorda Therapeutics’ board. She brings experience from Merck &Co and Synergy Partners R&D Solutions. ... Acorda Therapeutics has expanded its board of directors with the addition of Dr Catherine Strader.

  • Acorda Therapeutics appoints chief medical officer Acorda Therapeutics appoints chief medical officer

    New York-based biotech Acorda Therapeutics has appointed Dr Burkhard Blank as its chief medical officer. ... Burkhard brings to Acorda an impressive record of successful drug development and approved NDAs.

  • Acorda appoints new CFO Acorda appoints new CFO

    Acorda appoints new CFO. Michael Rodgers replaces David Lawrence who becomes chief business officer. ... I'm excited to take on this new challenge at Acorda, overseeing and optimising development of our business operations and infrastructure.”.

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics